Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain

被引:207
作者
Roberts, Rosalind F. [1 ,2 ]
Wade-Martins, Richard [1 ,2 ]
Alegre-Abarrategui, Javier [1 ,2 ]
机构
[1] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3QX, England
[2] Univ Oxford, Oxford Parkinsons Dis Ctr, Oxford OX1 3QX, England
关键词
alpha-synuclein; Parkinson's disease; oligomers; pathology; LEWY BODIES; PROXIMITY LIGATION; NEURODEGENERATIVE DISEASE; IN-SITU; PROTEIN; DEMENTIA; FORMS; PROTOFIBRILS; TRANSMISSION; OCCURS;
D O I
10.1093/brain/awv040
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Oligomeric forms of alpha-synuclein are emerging as key mediators of pathogenesis in Parkinson's disease. Our understanding of the exact contribution of alpha-synuclein oligomers to disease is limited by the lack of a technique for their specific detection. We describe a novel method, the alpha-synuclein proximity ligation assay, which specifically recognizes alpha-synuclein oligomers. In a blinded study with post-mortem brain tissue from patients with Parkinson's disease (n = 8, age range 73-92 years, four males and four females) and age-and sex-matched controls (n = 8), we show that the alpha-synuclein proximity ligation assay reveals previously unrecognized pathology in the form of extensive diffuse deposition of alpha-synuclein oligomers. These oligomers are often localized, in the absence of Lewy bodies, to neuroanatomical regions mildly affected in Parkinson's disease. Diffuse alpha-synuclein proximity ligation assay signal is significantly more abundant in patients compared to controls in regions including the cingulate cortex (1.6-fold increase) and the reticular formation of the medulla (6.5-fold increase). In addition, the alpha-synuclein proximity ligation assay labels very early perikaryal aggregates in morphologically intact neurons that may precede the development of classical Parkinson's disease lesions, such as pale bodies or Lewy bodies. Furthermore, the alpha-synuclein proximity ligation assay preferentially detects early-stage, loosely compacted lesions such as pale bodies in patient tissue, whereas Lewy bodies, considered heavily compacted late lesions are only very exceptionally stained. The alpha-synuclein proximity ligation assay preferentially labels alpha-synuclein oligomers produced in vitro compared to monomers and fibrils, while stained oligomers in human brain display a distinct intermediate proteinase K resistance, suggesting the detection of a conformer that is different from both physiological, presynaptic alpha-synuclein (proteinase K-sensitive) and highly aggregated alpha-synuclein within Lewy bodies (proteinase K-resistant). These disease-associated conformers represent previously undetected Parkinson's disease pathology uncovered by the alpha-synuclein proximity ligation assay.
引用
收藏
页码:1642 / 1657
页数:16
相关论文
共 50 条
[41]   Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease [J].
Parnetti, Lucilla ;
Chiasserini, Davide ;
Persichetti, Emanuele ;
Eusebi, Paolo ;
Varghese, Shiji ;
Qureshi, Mohammad M. ;
Dardis, Andrea ;
Deganuto, Marta ;
De Carlo, Claudia ;
Castrioto, Anna ;
Balducci, Chiara ;
Paciotti, Silvia ;
Tambasco, Nicola ;
Bembi, Bruno ;
Bonanni, Laura ;
Onofrj, Marco ;
Rossi, Aroldo ;
Beccari, Tommaso ;
El-Agnaf, Omar ;
Calabresi, Paolo .
MOVEMENT DISORDERS, 2014, 29 (08) :1019-1027
[42]   Alpha-Synuclein Contribution to Neuronal and Glial Damage in Parkinson's Disease [J].
Saramowicz, Kamil ;
Siwecka, Natalia ;
Galita, Grzegorz ;
Kucharska-Lusina, Aleksandra ;
Rozpedek-Kaminska, Wioletta ;
Majsterek, Ireneusz .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (01)
[43]   Advances in understanding the function of alpha-synuclein: implications for Parkinson's disease [J].
Calabresi, Paolo ;
Di Lazzaro, Giulia ;
Marino, Gioia ;
Campanelli, Federica ;
Ghiglieri, Veronica .
BRAIN, 2023, 146 (09) :3587-3597
[44]   Alpha-Synuclein and Oxidative Stress Enzymes as Biomarkers of Parkinson's Disease [J].
Goncharova, Z. A. ;
Kolmakova, T. S. ;
Gelpei, M. A. .
NEUROCHEMICAL JOURNAL, 2017, 11 (02) :121-128
[45]   Alpha-Synuclein Effects on Mitochondrial Quality Control in Parkinson's Disease [J].
Shen, Lydia ;
Dettmer, Ulf .
BIOMOLECULES, 2024, 14 (12)
[46]   Alpha-Synuclein Polymorphisms are Associated with Parkinson's Disease in a Saskatchewan Population [J].
Rajput, Alex ;
Vilarino-Guell, Carles ;
Rajput, Michele L. ;
Ross, Owen A. ;
Soto-Ortolaza, Alexandra I. ;
Lincoln, Sarah J. ;
Cobb, Stephanie A. ;
Heckman, Michael G. ;
Farrer, Matthew J. ;
Rajput, Ali .
MOVEMENT DISORDERS, 2009, 24 (16) :2411-2414
[47]   Parkinson's Disease: A Nanotheranostic Approach Targeting Alpha-Synuclein Aggregation [J].
Zoey, Fong LaiGuan ;
Palanivel, Mathangi ;
Padmanabhan, Parasuraman ;
Gulyas, Balazs .
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
[48]   The Peripheral Inflammatory Response to Alpha-Synuclein and Endotoxin in Parkinson's Disease [J].
White, Alice J. ;
Wijeyekoon, Ruwani S. ;
Scott, Kirsten M. ;
Gunawardana, Nushan P. ;
Hayat, Shaista ;
Solim, I. H. ;
McMahon, H. T. ;
Barker, Roger A. ;
Williams-Gray, Caroline H. .
FRONTIERS IN NEUROLOGY, 2018, 9
[49]   Detection of Dermal Alpha-Synuclein Deposits as a Biomarker for Parkinson's Disease [J].
Doppler, Kathrin .
JOURNAL OF PARKINSONS DISEASE, 2021, 11 (03) :937-947
[50]   Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles [J].
Richard M. Meade ;
David P. Fairlie ;
Jody M. Mason .
Molecular Neurodegeneration, 14